Company News »

Infinity Announces New Data for Duvelisib to Be Presented at the 2015 American Society of Clinical Oncology Annual Meeting

Business Wire
Share on StockTwits
Published on

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) today announced the upcoming poster presentations of new clinical, translational and preclinical data with duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago, Il. Duvelisib is the only dual inhibitor of PI3K-delta,gamma in Phase 3 clinical development and is in registration-focused studies in patients with indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). Infinity and AbbVie are jointly developing duvelisib in oncology.

Key results to be presented include new Phase 1 safety and efficacy data in patients with treatment-na”ive CLL, preclinical data that further support evaluating duvelisib in combination with other therapeutic agents including venetoclax, an investigational inhibitor of the BCL-2 protein, and translational data that support the role of PI3K-delta and PI3K-gamma in hematologic malignancies and the tumor microenvironment.

The following four presentations of duvelisib at ASCO 2015 will take place on Sunday, May 31, 2015, from 8:00 a.m. to 11:30 a.m. CDT (9:00 a.m. 12:30 p.m. ET) in South Hall A at McCormick Place:

Title: Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-, inhibitor, in patients with treatment-na”ive CLL (Abstract #7074)
Lead author: Manish R. Patel, MD, Sarah Cannon Research Institute/Florida Cancer Specialists
Session: Leukemia, Myelodysplasia, and Transplantation

Title: High throughput in vitro combination sensitivity screen in hematologic malignancies with the phosphoinositide-3-kinase (PI3K)- , inhibitor, duvelisib (Abstract #8559)
Lead author: Kerrie Faia, MS, Infinity Pharmaceuticals, Inc.
Session: Lymphoma and Plasma Cell Disorders

Title: Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K- , inhibitor (Abstract #7072)
Lead author: Mark Douglas, MS, Infinity Pharmaceuticals, Inc.
Session: Leukemia, Myelodysplasia, and Transplantation

Title: A phase 1b trial of duvelisib, a PI3K-, inhibitor, in combination with obinutuzumab in patients with CLLSLL previously treated with a Brutons tyrosine kinase inhibitor (BTKi) (Abstract # TPS7100)
Lead author: James Stewart Blachly, MD, Ohio State University Medical Center
Session: Leukemia, Myelodysplasia, and Transplantation

About Duvelisib

Duvelisib is an investigational, oral, dual inhibitor of phosophoinositide-3-kinase (PI3K)-delta and PI3K-gamma that is being jointly developed by Infinity Pharmaceuticals, Inc. and AbbVie Inc. in oncology. The PI3K pathway is known to play a critical role in regulating the growth and survival of certain types of blood cancers. Duvelisib is designed to block the growth and survival of tumor cells by inhibiting PI3K-delta and PI3K-gamma signaling.

Duvelisib is being evaluated in registration-focused studies, including DYNAMOTM, a Phase 2 study in patients with refractory indolent non-Hodgkin lymphoma, DYNAMO+R, a Phase 3 study in patients with previously treated follicular lymphoma, and DUOTM, a Phase 3 study in patients with relapsed/refractory chronic lymphocytic leukemia. Duvelisib is also being evaluated in CONTEMPO, a Phase 1b/2 study in treatment-na”ive patients with follicular lymphoma and SYNCHRONY, a Phase 1b study in CLL patients whose disease is refractory to or has relapsed while receiving a BTK inhibitor.

Duvelisib is an investigational compound and its safety and efficacy have not been evaluated by the U.S. Food and Drug Administration or any other health authority.

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. For more information on Infinity, please refer to the companys website at

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including those regarding the companys expectations about the timing and type of data presentations and the therapeutic potential of PI3K-delta, gamma inhibition and of duvelisib, alone or in combination with other agents. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the companys current expectations, including, for example, that there is no guarantee that duvelisib will successfully complete necessary preclinical and clinical development phases, or gain regulatory approval, that Infinitys strategic collaboration with AbbVie will continue, and other risks described in greater detail under the caption Risk Factors included in Infinitys quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 6, 2015, and other filings filed by Infinity with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Share on StockTwits